2.52
-0.12(-4.55%)
Currency In USD
| Previous Close | 2.64 |
| Open | 2.65 |
| Day High | 2.66 |
| Day Low | 2.5 |
| 52-Week High | 5 |
| 52-Week Low | 1.11 |
| Volume | 1.1M |
| Average Volume | 2.12M |
| Market Cap | 670.67M |
| PE | -2.86 |
| EPS | -0.88 |
| Moving Average 50 Days | 2.1 |
| Moving Average 200 Days | 2.36 |
| Change | -0.12 |
If you invested $1000 in Autolus Therapeutics plc (AUTL) since IPO date, it would be worth $100.8 as of July 26, 2025 at a share price of $2.52. Whereas If you bought $1000 worth of Autolus Therapeutics plc (AUTL) shares 5 years ago, it would be worth $177.46 as of July 26, 2025 at a share price of $2.52.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
GlobeNewswire Inc.
Jul 24, 2025 11:30 AM GMT
LONDON and GAITHERSBURG, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
GlobeNewswire Inc.
Jul 21, 2025 11:00 AM GMT
Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicityEC approval follows positive CHMP opinion, MHRA conditional marketing autho
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jul 15, 2025 8:05 PM GMT
LONDON & GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and cand